These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 18356692

  • 1. Phosphorylated troglitazone activates PPARgamma and inhibits vascular smooth muscle cell proliferation and proteoglycan synthesis.
    Little PJ, Ballinger ML, Survase S, Osman N, Ogru E, Geytenbeek S, Bruemmer D, Nigro J.
    J Cardiovasc Pharmacol; 2008 Mar; 51(3):274-9. PubMed ID: 18356692
    [Abstract] [Full Text] [Related]

  • 2. Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents.
    de Dios ST, Frontanilla KV, Nigro J, Ballinger ML, Ivey ME, Cawson EA, Little PJ.
    J Diabetes Complications; 2007 Mar; 21(2):108-17. PubMed ID: 17331859
    [Abstract] [Full Text] [Related]

  • 3. Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity.
    Lee KS, Park JH, Lee S, Lim HJ, Jang Y, Park HY.
    Biochem Biophys Res Commun; 2006 Jul 21; 346(1):83-8. PubMed ID: 16759638
    [Abstract] [Full Text] [Related]

  • 4. Troglitazone, a peroxisome proliferator-activated receptor-gamma agonist, decreases tau phosphorylation in CHOtau4R cells.
    d'Abramo C, Ricciarelli R, Pronzato MA, Davies P.
    J Neurochem; 2006 Aug 21; 98(4):1068-77. PubMed ID: 16787414
    [Abstract] [Full Text] [Related]

  • 5. Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts.
    Zhang GY, Yi CG, Li X, Ma B, Li ZJ, Chen XL, Guo SZ, Gao WY.
    Br J Dermatol; 2009 Apr 21; 160(4):762-70. PubMed ID: 19120328
    [Abstract] [Full Text] [Related]

  • 6. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
    Colin C, Salamone S, Grillier-Vuissoz I, Boisbrun M, Kuntz S, Lecomte J, Chapleur Y, Flament S.
    Breast Cancer Res Treat; 2010 Nov 21; 124(1):101-10. PubMed ID: 20054646
    [Abstract] [Full Text] [Related]

  • 7. Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells.
    Asano M, Nakajima T, Iwasawa K, Morita T, Nakamura F, Imuta H, Chisaki K, Yamada N, Omata M, Okuda Y.
    Br J Pharmacol; 1999 Oct 21; 128(3):673-83. PubMed ID: 10516648
    [Abstract] [Full Text] [Related]

  • 8. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.
    Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA.
    J Clin Invest; 1996 Oct 15; 98(8):1897-905. PubMed ID: 8878442
    [Abstract] [Full Text] [Related]

  • 9. Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor gamma.
    Li X, Yang X, Xu Y, Jiang X, Li X, Nan F, Tang H.
    Cell Res; 2009 Jun 15; 19(6):720-32. PubMed ID: 19417774
    [Abstract] [Full Text] [Related]

  • 10. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
    Schiefelbein D, Seitz O, Goren I, Dissmann JP, Schmidt H, Bachmann M, Sader R, Geisslinger G, Pfeilschifter J, Frank S.
    Mol Pharmacol; 2008 Oct 15; 74(4):952-63. PubMed ID: 18599600
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Activation of a retinoic acid receptor pathway by thiazolidinediones induces production of vascular endothelial growth factor/vascular permeability factor in OP9 adipocytes.
    Kotake D, Hirasawa N.
    Eur J Pharmacol; 2013 May 05; 707(1-3):95-103. PubMed ID: 23542713
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Troglitazone acutely activates AMP-activated protein kinase and inhibits insulin secretion from beta cells.
    Wang X, Zhou L, Shao L, Qian L, Fu X, Li G, Luo T, Gu Y, Li F, Li J, Zheng S, Luo M.
    Life Sci; 2007 Jun 20; 81(2):160-5. PubMed ID: 17544010
    [Abstract] [Full Text] [Related]

  • 19. Effect of troglitazone on CYP1A1 induction.
    Kim HG, Han EH, Jeong HG.
    Toxicology; 2008 Apr 18; 246(2-3):166-71. PubMed ID: 18308446
    [Abstract] [Full Text] [Related]

  • 20. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
    Yu HN, Lee YR, Noh EM, Lee KS, Kim JS, Song EK, Han MK, Lee YC, Kwon KB, Lee SJ, Youn HJ, Jung SH.
    Cell Biol Int; 2008 Aug 18; 32(8):906-12. PubMed ID: 18474441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.